Financial Performance - For the fiscal year ending December 31, 2023, the group's revenue decreased by 27.5% to HKD 65.0 million, compared to HKD 89.7 million in the fiscal year 2022[5]. - The group's gross profit for the fiscal year 2023 decreased by 32.9% to HKD 56.3 million, down from HKD 83.8 million in the previous year[5]. - The group's profit after tax increased by 259.9% to HKD 2.5 million for the fiscal year 2023, compared to HKD 0.7 million in fiscal year 2022[5]. - The total comprehensive loss for the fiscal year 2023 amounted to HKD 4.95 million, compared to a loss of HKD 69.61 million in fiscal year 2022[8]. - The adjusted profit before tax for the year ended December 31, 2023, was HKD 4,745,000, compared to HKD 9,323,000 in 2022, indicating a decrease of about 49.1%[22][24]. - The company reported a net profit of HKD 2,313,000 for 2023, compared to a net loss of HKD 904,000 in 2022[40]. - The annual profit for fiscal year 2023 was approximately HKD 2,523,000, compared to a profit of HKD 701,000 in fiscal year 2022[54]. Assets and Liabilities - The group's net assets increased by 2.3% to HKD 430.5 million, up from HKD 420.8 million in the previous year[5]. - The group's total assets less current liabilities stood at HKD 435.9 million, compared to HKD 421.5 million in fiscal year 2022[10]. - The total assets as of December 31, 2023, amounted to HKD 509,254,000, an increase from HKD 484,839,000 in 2022, reflecting a growth of approximately 5.0%[26]. - The total liabilities as of December 31, 2023, were HKD 78,789,000, up from HKD 63,990,000 in 2022, which is an increase of about 23.1%[26]. - As of December 31, 2023, the group's net current assets amounted to approximately HKD 250,127,000, an increase from HKD 246,217,000 in the fiscal year 2022[67]. - The group had cash and cash equivalents of approximately HKD 81,075,000 as of December 31, 2023, compared to HKD 60,069,000 in the fiscal year 2022, reflecting a significant increase[67]. Earnings Per Share - The group's basic and diluted earnings per share for fiscal year 2023 were HKD 0.15, compared to a loss of HKD 0.06 per share in the previous year[7]. - Basic and diluted earnings per share for 2023 were HKD 0.00149, compared to a loss per share of HKD 0.0006 in 2022[40]. Dividends - The board of directors did not recommend a final dividend for the fiscal year 2023, consistent with the previous year[5]. - The company did not declare or recommend any dividends for 2023, consistent with 2022[39]. - No dividends were proposed for the fiscal year 2023, consistent with the previous fiscal year[90]. Segment Performance - The company reported a segment loss of HKD 24,016,000 in the longevity science business for the year ended December 31, 2023, compared to a profit of HKD 8,953,000 in 2022[22][24]. - The longevity science segment generated revenue of approximately HKD 31,326,000, down from HKD 43,920,000 in fiscal year 2022, with a segment loss of HKD 24,016,000[57]. - The lending and financial consulting segment recorded revenue of approximately HKD 33,663,000, a decrease from HKD 45,748,000 in fiscal year 2022, with a segment profit of HKD 25,354,000[61]. Cash Flow and Financial Costs - The group's cash and cash equivalents increased to HKD 81.1 million in fiscal year 2023, up from HKD 60.1 million in the previous year[10]. - The company's financial cost for the year ended December 31, 2023, was HKD (1,936,000), compared to HKD (417,000) in 2022, indicating an increase in financial costs[22][24]. Compliance and Governance - The audit committee, consisting of three independent non-executive directors, has reviewed and approved the consolidated financial statements for the fiscal year 2023, ensuring compliance with applicable accounting standards and regulations[97]. - The company has adopted the standard code of conduct for securities trading by directors, confirming compliance throughout the year[96]. - The company is committed to enhancing its internal control systems to prevent future delays in financial reporting as per listing rules[93]. - The risk management committee has monitored the company's adherence to risk management and internal control guidelines[94]. - The chairman of the board, Yan Li, confirmed the board's commitment to overseeing the effectiveness of risk management and internal control systems[101]. Future Plans and Strategies - The company aims to achieve global leadership in the sales revenue of lipid-lowering biological products by 2024, with the competitive product ZJ1 VC being used in over 117 countries[47]. - The company plans to replicate its standardized longevity management services in 26 major cities globally, enhancing its brand image among high-net-worth individuals[49]. - The company plans to continue expanding its longevity science business and may consider forming joint ventures with strategic partners to maximize shareholder returns[83]. - A joint venture agreement was signed on February 26, 2024, to establish a company in China focused on the trade of biopharmaceutical products, with the group holding a 51% stake[88].
中基长寿科学(00767) - 2023 - 年度业绩